Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income towards Parent Company (2016 - 2025)

Lineage Cell Therapeutics' Income towards Parent Company history spans 16 years, with the latest figure at -$6.2 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 89.38% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$34.9 million, down 87.97%, while the annual FY2025 figure was -$63.4 million, 241.01% down from the prior year.
  • Income towards Parent Company reached -$6.2 million in Q4 2025 per LCTX's latest filing, down from -$3.4 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$1.4 million in Q1 2021 to a low of -$28.0 million in Q4 2021.
  • Average Income towards Parent Company over 5 years is -$7.2 million, with a median of -$6.1 million recorded in 2022.
  • The largest YoY upside for Income towards Parent Company was 82.82% in 2021 against a maximum downside of 2946.44% in 2021.
  • A 5-year view of Income towards Parent Company shows it stood at -$28.0 million in 2021, then skyrocketed by 77.43% to -$6.3 million in 2022, then grew by 25.42% to -$4.7 million in 2023, then soared by 31.06% to -$3.2 million in 2024, then crashed by 89.38% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Income towards Parent Company are -$6.2 million (Q4 2025), -$3.4 million (Q3 2025), and -$19.3 million (Q2 2025).